Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health (ELAN) delivers innovative health solutions for pets and livestock worldwide. This dedicated news hub provides investors and industry professionals with essential updates on corporate developments, product innovations, and strategic initiatives shaping the animal health sector.
Access real-time press releases, earnings announcements, and regulatory filings alongside analysis of ELAN's advancements in veterinary pharmaceuticals. Our curated collection simplifies tracking of:
- Quarterly financial results and investor communications
- New product launches and FDA approvals
- Strategic partnerships and R&D milestones
- Industry leadership initiatives and sustainability efforts
Bookmark this page for streamlined access to verified ELAN updates. Combine our news feed with SEC filings and market analysis tools for comprehensive due diligence in the dynamic animal health market.
Neurizon Therapeutics has entered into an exclusive global licensing agreement with Elanco Animal Health (NYSE:ELAN) for Monepantel, the key ingredient in NUZ-001, their lead investigational therapy for ALS and other neurodegenerative diseases.
The agreement includes exclusive worldwide rights to Elanco's intellectual property, access to non-clinical studies and manufacturing data, and outlines terms for a future GMP-compliant Monepantel supply agreement. Financial terms include a nominal upfront fee, development milestone payments of $9.75 million for initial products and $5.2 million for subsequent products, sales milestones up to $65 million, and single-digit royalties on global net sales.
A formal supply agreement is expected to be finalized in H2 2025, which will provide Neurizon with a long-term source of GMP-compliant monepantel for clinical development and commercialization.
Elanco Animal Health (NYSE:ELAN) has released its 2024 Impact Report, introducing a new framework focused on four key communities: animals, customers, society, and employees. The company achieved significant milestones including $461 million in innovation revenue from new products like Zenrelia and Credelio Quattro, exceeding their target of $420-450 million.
Key achievements include becoming the #1 retail parasiticide dispenser in the U.S., launching Bovaer® for methane reduction in dairy cattle, and enrolling 11% of U.S. dairy herds in their UpLook sustainability database. The company demonstrated strong social impact through $400,000 in product donations, 26,000 volunteer hours, and improved employee engagement scores of 71% in Q1 2025.
Elanco Animal Health (NYSE: ELAN) has appointed Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen, currently CFO at Hillenbrand, Inc., brings nearly three decades of finance leadership experience, including 15 years at Johnson Controls where he held various executive positions. He succeeds Todd Young, who will remain as an advisor through August 31, 2025.
The company is experiencing strong momentum with seven consecutive quarters of growth and is focusing on accelerating growth, globalizing innovation, expanding margins, and improving cash generation. Elanco also reconfirmed its second quarter and full year guidance issued during the May 7, 2025 earnings call.
Elanco Animal Health (NYSE: ELAN) has announced its management's participation in two upcoming investor conferences. CEO Jeff Simmons will attend the BNP Paribas 2nd Annual Animal Health Day on May 22, 2025, at 12:00 p.m. ET. Additionally, both Simmons and CFO Todd Young will participate in a fireside chat at the Stifel 2025 Jaws & Paws Conference on May 29, 2025, at 8:00 a.m. ET.
Both events will feature live audio webcasts accessible through Elanco's investor website under the "Events and Presentations" section, with replays available for a limited time after each event.
Elanco Animal Health (NYSE: ELAN) commemorates the second annual National Parvo Awareness Day, highlighting their breakthrough Canine Parvovirus Monoclonal Antibody (CPMA) treatment. The USDA-conditionally approved CPMA has demonstrated remarkable results with a 93% survival rate for infected puppies, reducing hospital stays by an average of 1.87 days.
Through ParvoTrack, Elanco's pioneering real-time outbreak tracking tool, thousands of cases have been reported nationwide, with Texas, Arizona, Georgia, Florida, Illinois, Indiana, and New York showing the highest outbreak rates. The platform enables pet owners and veterinarians to self-report cases and receive local outbreak alerts.
Elanco has set an ambitious goal to save 1 million puppies from parvovirus by 2030. The company has already saved thousands of puppies in the first year, with success stories including Cookie, Dolly, Patrick, Beatrix, Buster, Luna, and Mono, all of whom made full recoveries after CPMA treatment.
Elanco Animal Health (NYSE: ELAN) has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025. The company will host a conference call at 8:00 a.m. eastern time to discuss the quarterly performance with investors, media, and the general public.
A live webcast of the conference call will be accessible through Elanco's investor relations website. Additionally, a replay of the call will be made available on the same platform following the event.